Laurus Labs FY26 revenue rises 23% to Rs 6,813 Crore; EBITDA surges 64%
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Subscribe To Our Newsletter & Stay Updated